EA201591894A1 - Регулятор паппализина - Google Patents
Регулятор паппализинаInfo
- Publication number
- EA201591894A1 EA201591894A1 EA201591894A EA201591894A EA201591894A1 EA 201591894 A1 EA201591894 A1 EA 201591894A1 EA 201591894 A EA201591894 A EA 201591894A EA 201591894 A EA201591894 A EA 201591894A EA 201591894 A1 EA201591894 A1 EA 201591894A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- human
- polypeptide
- mammalian subject
- alleviating
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24079—Pappalysin-1 (3.4.24.79)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Предложен способ уменьшения или увеличения активности полипептида паппализина посредством уменьшения или увеличения уровня взаимодействующих полипептидов паппализина и станниокальцина. Также предложен способ предотвращения, лечения или облегчения клинического состояния у субъекта-млекопитающего, такого как человек, причем указанный способ включает введение указанному субъекту-млекопитающему, такому как человек, эффективного количества полипептида станниокальцина. Кроме того, предложен способ предотвращения, лечения или облегчения клинического состояния у субъекта-млекопитающего, такого как человек, причем указанный способ включает введение указанному субъекту-млекопитающему, такому как человек, эффективного количества средства, способного выступать антагонистом взаимодействия полипептида станниокальцина с полипептидом паппализином.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201370259 | 2013-05-10 | ||
PCT/DK2014/050131 WO2014180485A2 (en) | 2013-05-10 | 2014-05-12 | Pappalysin regulator |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201591894A1 true EA201591894A1 (ru) | 2016-04-29 |
Family
ID=50943008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591894A EA201591894A1 (ru) | 2013-05-10 | 2014-05-12 | Регулятор паппализина |
Country Status (9)
Country | Link |
---|---|
US (2) | US20160151405A1 (ru) |
EP (1) | EP2994158A2 (ru) |
JP (1) | JP2016520583A (ru) |
CN (1) | CN105263510A (ru) |
CA (1) | CA2911933A1 (ru) |
EA (1) | EA201591894A1 (ru) |
HK (1) | HK1215929A1 (ru) |
MX (1) | MX2015015519A (ru) |
WO (1) | WO2014180485A2 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202235618A (zh) * | 2021-01-05 | 2022-09-16 | 美國馬友醫藥教育研究基金會 | 治療眼內壓相關疾患 |
WO2022270926A1 (ko) * | 2021-06-22 | 2022-12-29 | 동아대학교 산학협력단 | 다양한 암의 진단, 전이 또는 예후 예측용 신규한 바이오마커 및 이의 용도 |
WO2024042220A1 (en) * | 2022-08-25 | 2024-02-29 | Aarhus Universitet | Modulators of papp-a activity |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994103A (en) * | 1995-06-02 | 1999-11-30 | Human Genome Science, Inc. | Human stanniocalcin-alpha |
CA2387685A1 (en) * | 1999-10-27 | 2001-05-03 | Human Genome Sciences, Inc. | Stanniocalcin proteins and nucleic acids and methods based thereon |
JP2003525595A (ja) | 1999-11-01 | 2003-09-02 | キュラゲン コーポレイション | 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法 |
US20050009136A1 (en) | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
WO2008101118A2 (en) | 2007-02-14 | 2008-08-21 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates |
US20100292303A1 (en) | 2007-07-20 | 2010-11-18 | Birrer Michael J | Gene expression profile for predicting ovarian cancer patient survival |
BRPI0907640A2 (pt) | 2008-01-25 | 2015-11-03 | Univ Aarhus | inibição exosítio-seletiva da atividade de papp-a contra igfbp-4 |
WO2010020004A1 (en) * | 2008-08-22 | 2010-02-25 | Children's Medical Research Institute | Compositions and methods for inhibition of adipogenesis and the treatment of obesity |
-
2014
- 2014-05-12 CN CN201480031999.4A patent/CN105263510A/zh active Pending
- 2014-05-12 EP EP14730423.2A patent/EP2994158A2/en not_active Withdrawn
- 2014-05-12 JP JP2016512227A patent/JP2016520583A/ja active Pending
- 2014-05-12 US US14/889,997 patent/US20160151405A1/en not_active Abandoned
- 2014-05-12 CA CA2911933A patent/CA2911933A1/en not_active Abandoned
- 2014-05-12 EA EA201591894A patent/EA201591894A1/ru unknown
- 2014-05-12 WO PCT/DK2014/050131 patent/WO2014180485A2/en active Application Filing
- 2014-05-12 MX MX2015015519A patent/MX2015015519A/es unknown
-
2016
- 2016-04-05 HK HK16103840.8A patent/HK1215929A1/zh unknown
-
2019
- 2019-10-11 US US16/599,706 patent/US11318158B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2014180485A2 (en) | 2014-11-13 |
CN105263510A (zh) | 2016-01-20 |
MX2015015519A (es) | 2016-07-21 |
WO2014180485A3 (en) | 2015-03-05 |
EP2994158A2 (en) | 2016-03-16 |
US20200261490A1 (en) | 2020-08-20 |
JP2016520583A (ja) | 2016-07-14 |
CA2911933A1 (en) | 2014-11-13 |
HK1215929A1 (zh) | 2016-09-30 |
US11318158B2 (en) | 2022-05-03 |
US20160151405A1 (en) | 2016-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022013172A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
TW201613588A (en) | Ophthalmic composition | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
TR201902516T4 (tr) | Glukagon-glp-1-gıp üçlü agonist bileşikleri. | |
PH12018501903A1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
AR089993A1 (es) | Macrociclos peptidomimeticos | |
EA201491699A1 (ru) | Лечение рака ингибиторами tor киназы | |
EA201591501A1 (ru) | Терапевтические средства на основе csf-1 | |
BR112013026976A2 (pt) | alfa glucosidade ácida modificada com processamento acelerado | |
EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
WO2015023691A3 (en) | 4-methylumbelliferone treatment for immune modulation | |
UA117480C2 (uk) | Лікування цукрового діабету за допомогою складу інсуліну тривалої дії | |
PH12015501709A1 (en) | Administration of an-activin-a compound to a subject | |
MX2016000220A (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
EA201591773A1 (ru) | Макроциклические ингибиторы rip2-киназы | |
EA201590061A1 (ru) | Фармацевтическая композиция | |
MX2015012580A (es) | El uso de sdf-1 para atenuar la formacion de cicatrices. | |
MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
EA201591894A1 (ru) | Регулятор паппализина | |
UA117933C2 (uk) | Поліпептид, здатний зв'язувати с5-компонент комплементу людини | |
EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
MX2016016650A (es) | Metodo para tratar el sindrome de mano-pie y sintomas asociados con el mismo. | |
NZ631639A (en) | Methods and compositions for treating and diagnosing acute myocardial infarction | |
MX2023006097A (es) | Metodos in vitro para la deteccion de mutaciones en neoplasmas intracraneales. |